Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642455 · ClinicalTrials.gov registry record · Phase 1
SPEARHEAD-3 Pediatric Study
A Phase 1 study of Osteosarcoma and Synovial Sarcoma, sponsored by Uswm CT.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 10
- Study locations
NCT05642455 is a Phase 1 study of Osteosarcoma and Synovial Sarcoma that is actively recruiting participants, run by Uswm CT. The registered enrollment target is 20 participants, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (93% lower). The trial reports 10 study locations across 10 states.
The verdict
NCT05642455, a Phase 1 study of Osteosarcoma and Synovial Sarcoma, is actively recruiting participants, sponsored by Uswm CT.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Conditions Studied
Interventions
- GENETIC Afamitresgene autoleucel
Study Locations (10)
California
- Stanford University - Palo Alto
Maryland
- National Institutes of Health - Bethesda
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Washington University - St Louis
New York
- Memorial Sloan Kettering Kids - New York
North Carolina
- Duke University School of Medicine - Durham
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philedephia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2038-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05642455
The ClinicalTrials.gov registry entry for NCT05642455 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (93% lower). The listed sponsor is Uswm CT, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Afamitresgene autoleucel is the first listed.
NCT05642455 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05642455 about?
NCT05642455 is a clinical study titled "SPEARHEAD-3 Pediatric Study". This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
What is the current status of trial NCT05642455?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-09-01. Estimated completion is 2038-07-30.
What conditions does trial NCT05642455 study?
This clinical trial studies the following conditions: Osteosarcoma, Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL).
What interventions are being tested in trial NCT05642455?
The interventions under investigation include: Afamitresgene autoleucel (GENETIC).
Who is sponsoring clinical trial NCT05642455?
This trial is sponsored by Uswm CT, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05642455 being conducted?
This trial has 10 study locations across California, Maryland, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Losartan + Sunitinib in Treatment of Osteosarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.